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ABSTRACT
Sox9, an SRY-related HMG box transcription factor, is a progenitor/precursor 
cell marker of the liver expressed during embryogenesis and following liver injury. 
In this study, we investigated the role of Sox9 and its molecular mechanism with 
reference to stemness properties in hepatocellular carcinoma (HCC). Here, we 
observed upregulation of Sox9 in human HCC tissues compared with the non-tumorous 
liver counterparts (p < 0.001). Upregulation of Sox9 transcript level was associated 
with poorer tumor cell differentiation (p = 0.003), venous invasion (p = 0.026), 
advanced tumor stage (p = 0.044) and shorter overall survival (p = 0.042). Transcript 
levels of Sox9 and CD24 were positively correlated. Silencing of Sox9 in HCC cells 
inhibited in vitro cell proliferation and tumorsphere formation, sensitized HCC cells 
to chemotherapeutic agents, and suppressed in vivo tumorigenicity. In addition, 
knockdown of Sox9 suppressed HCC cell migration, invasion, and in vivo lung 
metastasis. Further studies showed that Sox9 endowed stemness features through 
activation of Wnt/β-catenin signaling, which was confirmed by the partial rescue 
effect on tumorigenicity and self-renewal upon transfection of active β-catenin in Sox9 
knockdown cells. By ChIP and luciferase promoter assays, Frizzled-7 was identified 
to be the direct transcriptional target of Sox9. In conclusion, Sox9 confers stemness 
properties of HCC through Frizzled-7 mediated Wnt/β-catenin pathway. 
INTRODUCTION
Sox9 is a member of the sex-determining region 
Y (SRY)-related high-mobility-group box transcription 
factors. Sox proteins are heavily involved in human 
developmental process and regulate lineage restriction, 
cell differentiation and stem cell properties [1]. Among 
the Sox family, Sox9 promotes testis differentiation and 
cartilage formation. In the liver, Sox9 is expressed in the 
progenitor/precursor cells during embryogenesis and 
during hepatocyte regeneration following liver injury [2, 3].
Sox9 overexpression was found in human cancers 
including prostate, lung and colon cancers, and is 
associated with more aggressive clinicopathological 
features and poorer prognosis [4–6]. Silencing of Sox9 
inhibits cell growth and clonogenicity in lung cancer [7]. 
Abrogation of Sox9 blocks initiation of prostate cancer [8]. 
In esophageal cancer, Sox9 promotes tumorsphere 
formation and invasive capacity; and in colon cancer it 
enhances tumorigenicity [9, 10]. On signaling pathways, 
Sox9 binds directly to BMI1 in colon cancer [10], 
co-operates with slug to induce mammary stem cells in the 
breast [11], and drives tumorigenesis through the ERBB 
pathway in the pancreas [12]. 
In hepatocellular carcinoma (HCC), a recent study 
showed that Sox9 overexpression is associated with higher 
tumor stage and tumor grade and poorer survival [13]. 
While being a liver progenitor cell marker, the potential 
role and molecular mechanisms of Sox9 in conferring 
stem cell-like properties in HCC remain to be further 
elucidated. Cancer stem cells (CSCs)/tumor-initiating cells 
(T-ICs) in solid cancers share many of the characteristics of 
normal stem cells and drive tumor initiation, self-renewal, 
chemoresistance, tumor recurrence and metastasis [14, 15]. 
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In the liver, the existence and importance of CSC/T-IC have 
also been substantiated [16–18]. In this study, we aimed 
at investigating the functional significance of Sox9 and its 
downstream signaling pathway with specific reference to 
stemness features in HCC. 
RESULTS
Sox9 is overexpressed in human HCC
By qPCR we assessed the transcript levels of 
Sox9 in the tumor tissues and the corresponding non-
tumorous liver tissues in 69 human HCC samples. Sox9 
was overexpressed in HCC tissues compared to the non-
tumorous counterpart (p < 0.001). Sox9 upregulation 
(tumor/non-tumor ≥ 4) was observed in 32 cases 
(46.4%) (Figure 1A). Sox9 overexpression was also 
demonstrated at protein level by immunohistochemistry 
(IHC). Positive staining was detected in HCC cells while 
the hepatocytes in the non-tumorous tissue showed no 
staining (Figure 1B). A significant correlation between 
Sox9 mRNA and protein overexpression was observed 
(p = 0.0008) (Supplementary Table S1). The expression 
data in the clinical cohort were subjected to statistical 
correlation with various clinicopathological parameters in 
our database. Upregulation of Sox9 (by qPCR) in HCC 
was associated with poorer tumor cell differentiation 
(p = 0.003), venous invasion (p = 0.026), higher tumor 
stage (p = 0.044) and shorter overall survival (Table 1 
and Figure 1C). Furthermore, Sox9 transcript level in 
HCC tissues is positively correlated with that of CD24, 
our previously characterized liver T-IC marker [17] 
(Figure 1D). We also examined the immunohistochemical 
expression of stemness markers CK19, AFP and EpCAM 
in the clinical cohort. Seventeen cases (of 67 examined) 
showed positive CK19 staining. The percentage of 
positivity is similar to that reported previously [19]. 
Interestingly, all CK19+ cases were Sox9+, and 14 of 
the 17 CK19+ cases were demonstrating high Sox9 
immunoexpression. In addition, among the Sox9+ subset, 
majority of AFP+ and EpCAM+ cases (18/22 and 17/22 
for AFP and EpCAM respectively) was associated with a 
high Sox9 immunoexpression (Supplementary Figure S1 
and Supplementary Table S2). By Western blotting in a 
panel of HCC cell lines, Sox9 was abundantly expressed 
in BEL-7402, PLC/PRF/5, Huh7, Hep3B, MHCC- 97L 
and MHCC-97H cell lines, while the immortalized 
normal liver cell line LO2 showed no Sox9 expression 
(Figure 1E). 
Sox9 expression in HCC is associated with 
expression of stemness markers in vitro
In order to examine the phenotypic features and 
functional roles of Sox9, we established stable Sox9 
knockdown clones by a lentiviral-based approach in 
high Sox9-expressing Huh7 and Hep3B cells, and a 
transient Sox9 overexpression in low Sox9-expressing 
SMMC- 7721. Upon knockdown of Sox9 in HCC cells 
(Huh7 and Hep3B), we observed a downregulation of 
stemness-associated genes including BMI-1, CD133, 
Sox2, Nestin, Notch1 and Oct4, and chemoresistance-
related genes (ABCB1, ABCC6, ABCG2) by qPCR 
compared with non-target control (NTC). Overexpression 
of Sox9 in SMMC-7721 brought about the opposite 
effects (Figure 1F). The effect of Sox9 on Sox2 and 
Oct4 expression was further supported by Western 
blotting (Figure 1G). Besides, co-expression of CD24 
in Sox9-expressing SMMC-7721 cells was observed by 
immunofluorescence (IF) staining (Figure 1H). These 
findings suggest that Sox9 is associated with stemness 
features in HCC. 
Silencing of Sox9 reduces T-IC features of HCC 
cells
Since expression of Sox9 in HCC is associated with 
that of stemness-associated genes, we performed various 
T-IC assays through suppressing Sox9 expression by a 
lentiviral-based approach (Figure 2A). Silencing of Sox9 
(Huh7 and Hep3B) decreased HCC cell proliferation 
(Figure 2B). With non-adherent sphere formation assay, 
the numbers of tumorspheres were significantly decreased 
in the Sox9-knockdown clones compared with NTC, 
and size of the tumorspheres was also reduced in both 
primary and secondary generations (Figure 2C). Silencing 
of Sox9 suppressed the side population in Huh7 cells 
(Figure 2D). In order to validate our in vitro findings in a 
more biological environment, we performed subcutaneous 
inoculation in NOD/SCID mice to study the functional 
effects of Sox9. Stable knockdown of Sox9 suppressed 
tumorigenicity in vivo in a limited dilution manner 
(Figure 2E). Prolonged tumor latency period was also 
observed (Supplementary Figure S2). Through injection 
of 1 × 106 Huh7 cells, the tumor volume was significantly 
lower in shSox9 group at weeks 2–4 when compared with 
NTC group (Figure 2F).
Sox9 confers chemoresistance in HCC
Our experiments showed that silencing of Sox9 
inhibits tumorsphere formation in vitro and tumorigenicity 
in vivo. Chemoresistance is one of the major characteristics 
of T-ICs [16]. We found that knockdown of Sox9 
downregulates the expression of multiple chemoresistance-
related genes (Figure 1F). Hence we proceeded to study 
how Sox9 might alter chemosensitivity of HCC cells by 
apoptotic assays with Annexin V/PI staining. Silencing of 
Sox9 in HCC cells (Huh7 and Hep3B) increased the number 
of cells in apoptotic phase compared with NTC when 
treated with doxorubicin or cisplatin, and sensitized HCC 
cells to these chemotherapeutic agents. The opposite effects 
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were observed upon forced expression of Sox9 (Figure 3). 
The results suggest that Sox9 confers chemoresistance in 
HCC cells. 
Knockdown of Sox9 inhibits cell migration, 
invasion in vitro and metastasis of HCC in vivo
By statistical correlation, Sox9 upregulation is 
associated with venous invasion and advanced tumor stage 
(Table 1). Hence we proceeded to confirm whether Sox9 
facilitates HCC metastasis in vitro and in vivo. Silencing 
of Sox9 (Huh7 and Hep3B) decreased HCC cell migration 
(Figure 4A) and invasion (Figure 4B). With Western 
blotting and IF study, knockdown of Sox9 suppressed 
epithelial-mesenchymal transition (EMT) as demonstrated 
by upregulation of E-cadherin and downregulation of 
vimentin expressions (Figure 4C and Supplementary 
Figure S3). Next, we established the NTC and Sox9 
knockdown clones using luciferase labeled-BEL-7402 with 
lentiviral-based approach. The efficiency was validated 
using Western blotting. We then employed an experimental 
metastasis model in NOD/SCID mice to investigate the 
role of Sox9 in HCC metastasis. At 12th week after tail 
vein injection, the lung metastasis rate in shSox9 group 
Table 1: Clinicopathological correlation of Sox9 expression in human HCCs
Parameter Sox9 T:NT < 4 Sox9 T:NT ≥ 4 p value(Fisher’s Exact Test)
Gender
    Male 27 26
0.569
    Female 10 6
Tumor size
    ≤ 5 cm
    > 5 cm
17
19
10
22 0.219
Venous invasion
    Absent 20 8
0.026*
    Present 17 24
Tumor encapsulation
    Absent 21 25
0.066
    Present 15 6
Microsatellite formation
    Absent 19 11
0.141
    Present 16 21
Direct liver invasion
    Absent 19 19
1.000
    Present 11 11
Cellular differentiation
    Edmondson   (I–II) 22 8
    0.003**
    Edmondson (III–IV) 13 24
pTNM stage
    I/II 17 7
  0.044*
    III/IV 19 24
Non-tumorous liver
    Normal & chronic hepatitis 17 15
1.000
    Cirrhosis 20 17
Serum HBsAg
    Negative 6 5
1.000
    Positive 29 27
Upregulation of Sox9 in HCC was associated with poorer tumor cell differentiation (p = 0.003), presence of venous invasion 
(p = 0.026) and advanced tumor stage (p = 0.044).
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Figure 1: Sox9 is upregulated in human HCC and Sox9 expression is associated with expression of stemness markers 
in vitro. (A) Sox9 was significantly upregulated in HCC tumor (T) versus non-tumorous liver (NT) tissues by qPCR (n = 69; ***p < 0.001, 
Wilcoxon signed-rank test). Upregulation of Sox9 was found in (32/69) 46.4% of primary HCC cases. Data were presented as the log2 
ratio of Sox9 mRNA level in HCC tissues, as compared to the corresponding non-tumorous liver tissues. Upregulation was defined 
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(BEL-7402-LUC) was lower (1/6) than that of NTC (6/6). 
Quantification of the corresponding luciferase signals 
further demonstrated a significant difference between the 
two groups (Figure 4D), and the lung tissues were analyzed 
by histological examination (Figure 4E). 
Sox9 endows stemness features in HCC through 
the canonical Wnt pathway
By in vitro and in vivo experiments, we showed 
that Sox9 confers stemness features and metastatic 
capability of HCC cells. Next, we wished to elucidate the 
downstream signaling pathway of Sox9 that gives rise 
to these features. The interaction between Sox9 and the 
canonical Wnt pathway in various human processes has 
been described. Physiologically, Sox9 degrades β-catenin 
in chondrogenesis [20] while in pancreatic development 
Sox9 represses β-catenin degradation [21]. In both breast 
cancer and glioma, Sox9 facilitates Wnt/β-catenin signaling 
[22, 23]. Thus, the effect of Sox9 on Wnt/β-catenin pathway 
may vary in different cellular contexts and biological 
processes. In this connection, we proceeded to determine 
whether Sox9 confers stem cell-like phenotypes in HCC 
through the Wnt/β-catenin pathway. We first examined the 
expression of key target molecules of the canonical Wnt 
pathway, pGSK3β and β-catenin, in HCC cells with altered 
Sox9 expression. We observed that knockdown of Sox9 
suppressed the expression of phosphorylated (Ser9)-GSK3β 
and β-catenin, while total GSK3β level remained unchanged 
(Figure 5A). The expressions of axin2 and c-myc were 
also downregulated (Figure 5B and Supplementary 
Figure S4A). The reversed effects were observed with Sox9 
transient overexpression (Figure 5A and Supplementary 
Figure S4B). In addition, silencing of Sox9 resulted in a 
decrease in Wnt/β-catenin pathway activation by TOP/
FOPFlash reporter assay (Figure 5C and Supplementary 
Figure S4C). To further clarify the above findings, we 
performed rescue experiments by stably expressing 
constitutively active β-catenin plasmids (Plasmid 16520, 
Addgene, Cambridge, MA, USA) [24] in Sox9 knockdown 
cells. The effect with TOP/FOPFlash reporter assay in Sox9 
silencing clones (Huh7 and Hep3B) was abrogated upon 
β-catenin forced expression (Figure 5D). Forced expression 
of β-catenin partially rescued the effect of Sox9 silencing on 
tumorsphere formation assays (Figure 5E), and similarly the 
effects on tumorigenicity, tumor volume and tumor latency 
period in vivo (Figure 5F and Supplementary Figure S4D). 
Hence we believe that the canonical Wnt pathway is 
mediating the downstream effect of Sox9 in HCC. 
Sox9 activates canonical Wnt pathway through 
direct binding with Frizzled-7
Having consolidated the above findings, we 
attempted to extend our investigation on identifying 
the transcriptional target of Sox9 in the canonical Wnt 
pathway. With reference to the ChIP-sequencing data 
from a previous study by other groups [25], we examined 
whether Frizzled-7 (FZD7), a key receptor in Wnt/β-catenin 
pathway activation, would possibly be a downstream target 
of Sox9. FZD7 is overexpressed in human HCC [26] and 
activates the Wnt/β-catenin pathway [27, 28]. We found 
by qPCR and Western blotting FZD7 expression was 
suppressed in Sox9 knockdown clones compared with 
NTC. The reversed results were observed upon transient 
Sox9 overexpression (Figure 6A). Using the web-based 
prediction program ConSite for transcription factor binding 
analysis, several putative Sox9 binding sites were found on 
FZD7. ChIP assays results showed that Sox9 binds to FZD7 
at R1, R2 and R3 regions. Among these three regions, 
binding at R2 showed the highest fold of enrichment (17.52-
fold), while R1 with 2.84-fold and R3 with 8.40-fold when 
compared with normal rabbit IgG control (Figure 6B). 
To further confirm the direct binding of Sox9 on these 
regions, we examined the FZD7 promoter activity in Sox9 
expression-altered HCC cells using luciferase reporter 
assay. Significant decrease of signals was detected in all 
three regions in Sox9-silenced Huh7. Similar fold change of 
luciferase signals were detected at R1 (0.65- and 0.71-fold) 
and R3 (0.66- and 0.69-fold) in both knockdown clones 
#386 ad #388. The signals were significantly enhanced after 
Sox9-overexpression in SMMC-7721, with 3.12- and 3.14-
as log2 (T/ NT) ≥ 2. (B) Representative images of immunohistochemical staining for Sox9 in clinical HCC samples demonstrated the 
overexpression at protein level in HCC tissues, while the non-tumorous liver counterparts showed no staining among the hepatocytes. 
(C) Kaplan-Meier survival curve of overall survival in HCC patients with reference to Sox9 expression. Patients with Sox9 upregulation 
had lower overall 5-year overall survival rate (p = 0.0422, Kaplan-Meir Log-rank test). (D) Expressions of CD24 and Sox9 were positively 
correlated in clinical HCC samples. Expression level of CD24 and Sox9 in HCC samples was represented by ddCT (Tumor 18srRNA CT - Gene 
of interest CT 
− Non-tumor 18srRNA CT 
− Gene of interest CT) (n = 64, Pearson r = 0.3905, p < 0.01, Pearson’s correlation). (E) Sox9 was expressed in 
multiple HCC cell lines by Western blotting, including BEL-7402, PLC/PRF/5, Huh7, Hep3B, MHCC-97L and MHCC-97H. It was not 
detectable in immortalized liver cell line LO2. (F) Knockdown of Sox9 (clone #386) in Huh7 and Hep3B diminished the expression of 
multiple chemoresistance-related and stemness-associated genes when compared with non-target control (NTC), while overexpression 
of (OE) Sox9 in SMMC-7721 reversed the expressions compared with empty vector group (EV) (n = 3, *p < 0.05, **p < 0.01 & ***p < 
0.001, t test). The data were presented as mean ± SD. (G) Protein level of two stemness genes, Oct4 and Sox2, were suppressed in Huh7 
upon silencing of Sox9 and enhanced upon forced-expression of Sox9 in SMMC-7721. (H) CD24 expression was enhanced upon transient 
Sox9 overexpression in SMMC-7721 while it was not expressed in untransfected cell (without Sox9 signal) by immunofluorescent staining 
(Scale bar: 50 μm). 
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Figure 2: Silencing of Sox9 inhibits cell proliferation, tumorsphere formation and in vivo tumorigenicity in HCC. (A) Two 
Sox9 stable-knockdown clones (#386 and #388) were established in Huh7 and Hep3B using lentiviral-based shRNA approach. Both Sox9 
mRNA (n = 3, ***p < 0.001, t test) and protein levels were suppressed. (B) Knockdown of Sox9 inhibited cell proliferation in both Huh7 and 
Hep3B cells, when compared with NTC (n = 3, # p < 0.05, **/## p < 0.01 & ***p < 0.001, t test). (C) Knockdown of Sox9 reduced the number 
and size of the primary and secondary tumorspheres comparing with non-target control (NTC) in both Huh7 and Hep3B cell lines at Day 
10 and Day 15, respectively (n = 3, *p < 0.05, **p < 0.01 & ***p < 0.001, t test; Scale bar: 50 μm). The data were presented as mean ± SD. 
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fold at R1 and R3, respectively. The binding at R2 was most 
significantly suppressed by 0.52-fold in shSox9#386, while 
largely upregulated to 4.73-fold in Sox9-overexpressing 
SMMC-7721 when compared with the respective control 
groups, which agreed with our findings in ChIP assay of 
highest fold of enrichment detected at R2 (Figure 6C). 
This transcriptional relationship was further supported by 
a positive correlation of mRNA levels of FZD7 and Sox9 
in our clinical HCC cohort (Figure 6D). These findings 
suggest that Sox9 activates Wnt/β-catenin signaling 
through transcriptional regulation of FZD7 (followed by 
phosphorylation of GSK3β and the downstream events). 
DISCUSSION
In this study we demonstrated by expression analysis, 
together with in vitro and in vivo experiments, that Sox9 
endows stemness features in human HCC. Sox9 expression 
in HCC cells was associated with that of stemness 
markers. Silencing of Sox9 inhibited HCC proliferation, 
migration and invasion abilities and suppressed 
tumorsphere formation as well as side population. We also 
demonstrated that Sox9 confers chemoresistance in HCC. 
In vivo, silencing of Sox9 suppressed tumorigenicity and 
lung metastasis. We also found that Sox9 endows these 
properties in HCC through the canonical Wnt pathway. In 
addition, we demonstrated that FZD7, a key receptor of 
the pathway, is a direct transcriptional target of Sox9 in 
HCC. The summary of findings in this study is illustrated 
in Supplementary Figure S5. 
Sox9 in recent years has been identified as a stem/
progenitor cell marker for the liver and the pancreas [2]. 
It is suggested that Sox9 carries a progenitor cell function 
in some physiological and pathological processes. In our 
clinical cohort Sox9 is overexpressed in HCC tissues and 
associated with higher tumor grade, venous invasion, 
advanced tumor stage and poorer overall survival. 
These findings are similar to those reported by Guo 
et al. [13]. In the current study we additionally provided 
substantiating data through an in-depth characterization 
of Sox9 in HCC with an emphasis on stemness features. 
Our findings consolidated the role of Sox9 on conferring 
stemness properties in human HCC. A vast majority of 
HCC arises from a background of chronic liver disease 
(hepatitis virus infection, fatty liver disease, etc.) and 
the ensuing cirrhosis. Proliferation of Sox9+ progenitor 
cells during liver injury may be implicated in multi-step 
hepatocarcinogenesis. Sox9+ cells in HCC are possibly 
derived from Sox9+ liver progenitor cells. 
The canonical Wnt pathway is crucial in 
hepatocarcinogenesis [29]. In this regard, β-catenin 
mutation occurs in up to 40% of HCC [30] and it was well 
noted that a proportion of tumors showing accumulation 
of β-catenin protein do not carry β-catenin mutation [31]. 
In other words, heterogeneous regulatory mechanisms 
are involved in the activation of β-catenin. In this study, 
we showed that Sox9 confers HCC stemness properties 
through Wnt/β-catenin signaling. Moreover, we proved 
that Sox9, as a transcription factor, drives the transcription 
of FZD7, a key receptor of the canonical Wnt pathway in 
HCC. These findings enrich our understanding on Wnt/β-
catenin signaling in hepatocarcinogenesis, in which Sox9 
is an important and indispensible player. Recent works 
suggested that FZD7 emerges as a crucial regulator for 
stemness features in both human embryonic stem cells and 
cancer stem cells [32, 33]. Activation in the Wnt/β-catenin 
pathway through FZD7 may carry specific implications in 
the context of cancer stemness. The findings in our study 
suggest that Sox9/FZD7/Wnt signaling is implicated in 
endowing stemness properties of HCC. 
In this study we identified the downstream 
target and signaling pathway of Sox9 in HCC. What 
remains to be a question is the regulatory mechanism 
of Sox9 expression in this cancer. In breast cancer, Wnt 
increases Sox9 expression [22]. In lung and esophageal 
cancers Sox9 is activated by Notch pathway [9, 34] 
and in the esophagus, Sox9 is also a YAP1 target [35]. 
While in HCC, suppression of Sox9 by miRNA-101 
and miRNA-145 inhibits tumor proliferation, migration 
and invasion [36]. There is also evidence that activation 
of Notch and β-catenin pathways increases Sox9+ cells 
in HCC [37, 38]. Apart from that, Sox9 expression is 
upregulated by hypoxia in ovarian cancer [39]. Hypoxia 
is known to be associated with cancer stemness [40]. In 
view of this we retrieved our RNA sequencing data on 
hypoxia (1% O2) treated HCC cells and compared that 
under normoxic condition (20% O2). On the whole, we 
observed no drastic upregulation of Sox9 RNA copy 
number under hypoxic condition. The fold change in 
PLC/PRF/5, SMMC-7721, Hep3B, and MHCC-97L is 
3.330, 1.856, 0.796 and 1.796 respectively. Thus hypoxia 
may not be a sufficient mechanism for Sox9 upregulation 
in HCC. Lines of evidences have shown promoter site 
hypomethylation is an epigenetic hallmark for genes 
(D) Knockdown of Sox9 suppressed the side population (SP, shSox9#386: 0.137% & shSox9#388: 0.322%) when compared with non-target 
control (NTC) (1.12%) using Hoechst 33342 labeling. Reserpine sensitivity (lower panel) was used to verify the SPs and to determine 
optimal staining conditions. (E) Silencing of Sox9 suppressed tumorigenicity in vivo in limited dilution manner of 1 × 104 and 5 × 104 Huh7 
cells. Knockdown of Sox9 decreased tumor volume compared with non-target control (NTC) group (Black dotted circle: NTC; **p < 0.01, 
Mann-Whitney’s U test; Scale bar: 1 cm). Suppression of Sox9 showed a decrease in tumor incidence with both cell numbers injected. 
(F) Huh7 NTC and Huh7 shSox9 cells were injected subcutaneously into NOD/SCID mice (4 mice per group, 1 × 106 cells injected per 
mouse). Mice were sacrificed at week 4. Knockdown of Sox9 significantly suppressed HCC tumor growth and volume comparing with non-
target control (NTC) group (Red arrow: NTC; Blue arrow: shSox9#386; *p < 0.05; Scale bar: 1 cm). The data were presented as mean ± SD.
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Figure 3: Sox9 confers chemoresistance in HCC. Cells with stably knockdown of Sox9 were more chemosensitive to both 
(A) doxorubicin at 0.5 μg/mL for Huh7 and 1.5 μg/mL for Hep3B (n = 3, *p < 0.05, t test), and (B) cisplatin at 5 μg/mL for Huh7 and 
10 μg/ mL for Hep3B when compared with non-target control (NTC) group after 24-hour treatment at serum free condition (n = 3, **p < 0.01 
& ***p < 0.001, t test). Representative Annexin V-PI flow analysis plots of each treatment were shown. (C) Sox9-overexpressing SMMC-
7721 cells were more chemoresistant to both doxorubicin at 1 μg/mL and cisplatin 5 μg/mL when compared with empty vector (EV) group 
(n = 3, ***p < 0.001, t test). Representative Annexin V-PI flow analysis plots of each treatment were shown. 
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Figure 4: Silencing of Sox9 inhibits cell migration, invasion in vitro and metastasis of HCC in vivo. Knockdown of Sox9 
inhibited (A) cell migration ability and (B) invasiveness in both Huh7 and Hep3B cells, when compared with non-target control (NTC) 
(n = 3, *p < 0.05, **p < 0.01 & ***p < 0.001, t test; Scale bar: 50 μm). (C) Protein expression of E-cadherin was upregulated while 
vimentin was downregulated upon silencing of Sox9 as demonstrated by Western blotting, signifying inhibition of epithelial-mesenchymal 
transition with knockdown of Sox9. (D) Sox9 stable-knockdown clone and NTC were established in BEL-7402 luciferase-labeled cells using 
lentiviral-based shRNA approach. The efficiency of Sox9 silencing was confirmed by Western blotting. Ex vivo xenogen imaging of lungs 
at 12th week upon injection of either Sox9 silenced or NTC luciferase-labeled BEL-7402 through tail veins of NOD/SCID mice (6 mice per 
group, 1 × 106 cells injected per mouse). Quantification of luciferase signals showed significant difference between the shSox9 and NTC 
groups (**p < 0.01, Mann-Whitney’s U test). (E) Hematoxylin and eosin staining of mouse lung tissues from NTC and shSox9#386 groups 
indicated the suppression of pulmonary metastasis upon silencing of Sox9. Representative images were shown (Magnification: 200×).
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Figure 5: Sox9 enhances stemness features of HCC through Wnt/β-catenin signaling. (A) Silencing of Sox9 downregulated 
the expression of phosphorylated (Ser9)-GSK3β and total β-catenin in Huh7 using Western blotting. The reversed effects were observed 
upon Sox9 overexpression in SMMC-7721. (B) Sox9 silencing (Huh7) suppressed the mRNA levels of c-myc and axin2. (n = 3, *p < 0.05, 
**p < 0.01 & ***p < 0.001, t test). (C) Knockdown of Sox9 suppressed the activation of Wnt/β-catenin signaling cascade in Huh7 using 
TOP/FOPFLASH luciferase assay (n = 3, **p < 0.01, t test). (D) Stable expression of β-catenin was enforced in shSox9 clone (#386) 
in Huh7 and Hep3B and validated using Western blotting. The suppression of Wnt/β-catenin signaling activity was partially rescued in 
shSox9 knockdown cells upon enforcement of β-catenin when compared with empty vector (EV) group (n = 3, *p < 0.05, **p < 0.01, 
t test). (E) The suppression of tumorsphere formation ability through knockdown of Sox9 was partially rescued upon β-catenin enforcement 
(n = 3, *p < 0.05, **p < 0.01, t test; Scale bar: 100 μm). The data were presented as mean ± SD. (F) β-catenin or EV-expressing-shSox9 
silencing and EV-expressing Huh7-NTC were subcutaneously inoculated in NOD/SCID mice using 5 × 103 and 1 × 104 cells for 70 and 
60 days, respectively. Upon β-catenin enforcement, the tumorigenicity of Sox9 silenced cells was partially rescued (n = 9, results from 
two independent experiments for 5 × 103 group; n = 8 for 1 × 104 group, **p < 0.01 & ***p < 0.001, Mann-Whitney’s U test; Scale bar: 1 cm). 
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Figure 6: Frizzled-7 (FZD7) is a transcriptional target of Sox9 in HCC. (A) FZD7 was suppressed at mRNA (n = 3, *p < 0.05 & 
***p < 0.001, t test) and protein levels in Sox9 knockdown Huh7. The reversed effects were observed upon Sox9 overexpression in SMMC-
7721. The data were presented as mean ± SD. (B) Chromatin immunoprecipitation (ChIP) assay using Sox9 antibody and normal rabbit IgG 
in Huh7. Schematic diagram indicated the putative binding sites of Sox9 (+684 bp as R1, +276 bp as R2, –944 bp & –956 bp as R3, –1928 bp 
as R4) on FZD7 promoter and exon 1 region (Yellow box: Sox9 putative binding site; Black arrow: primer for ChIP assay). Sox9 bound 
to R1, R2 and R3, but not R4 in Huh7 cells (n = 3, *p < 0.05 & **p < 0.01, t test). (C) A significant decrease of signals was detected in 
silenced Sox9 Huh7 comparing with non-target control (NTC) group, while the signals were upregulated in Sox9-overexpressing SMMC-
7721 comparing with EV transfected group using luciferase reporter assay in R1, R2 and R3. (n = 3, *p < 0.05, **p < 0.01 & ***p < 0.001, 
t test). The data were presented as mean ± SD. (D) A positive correlation between FZD7 and Sox9 mRNA expressions was found in clinical 
HCC samples. Expression level of FZD7 and Sox9 in paired HCC samples was represented by ddCT (Tumor 18srRNA CT - Gene of interest CT - Non-
tumor 18srRNA CT - Gene of interest CT) (n = 66, Pearson r = 0.252, p < 0.05, Pearson’s correlation). 
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conferring CSC properties [41]. Moreover, epigenetic 
regulation of Sox9 expression by DNA methylation was 
observed in pancreatic cancer [42]. In this connection, 
DNA methylation of Sox9 promoter region possibly 
determines Sox9 expression levels in liver tissues. 
Our findings suggest that Sox9 could serve as a 
molecular target with prognostic significance in HCC, as 
well as a predictive marker for chemotherapy response. 
Being remarkably crucial in regulating multiple stemness 
properties including metastasis, Sox9 is possibly a critical 
therapeutic target for HCC so as to improve clinical 
outcome and patient survival. Use of specific inhibitors is 
one of the potential approaches to suppress the oncogenic 
functions Sox9 in HCC and to augment treatment effects 
of current chemotherapeutic agents. Further dissection 
of the epigenetic regulation of Sox9 expression in this 
cancer may also provide insights on the therapeutic 
perspective. 
MATERIALS AND METHODS
Human HCC samples
Human tissues in the HCC cohort were obtained 
from patients with liver resection at Queen Mary Hospital, 
Hong Kong and randomly selected for the current study. 
All specimens collected were either snap-frozen in liquid 
nitrogen and stored at –80 oC, or fixed in 10% formalin for 
paraffin embedding. Frozen sections from tissue samples 
were cut and stained for histological examination to ensure 
homogenous cell population. Use of human specimens 
was approved by the Institutional Review Board of the 
University of Hong Kong/Hospital Authority Hong Kong 
West Cluster (Reference Number UW 14-049).
Cell line models
Human HCC cell lines BEL-7402, SMMC-7721, 
PLC/PRF/5, Huh7, Hep3B, HepG2, MHCC-97L, MHCC-
97H and immortalized normal liver cell line LO2 were 
used. BEL-7402 and SMMC-7721 were obtained from 
Shanghai Institute of Cell Biology. PLC/PRF/5, Hep3B 
and HepG2 were purchased from American Type Culture 
Collection (Manassas, VA). MHCC-97L and MHCC-97H 
were gifts from Professor Z.Y. Tang at Fudan University. 
Huh7 was from Dr. H. Nakabayashi at Hokkaido 
University School of Medicine. LO2 was from Dr. J.R. 
Gu at the Shanghai Cancer Institute.
Sox9 knockdown and overexpressing HCC cells
To establish Sox9 knockdown clones, recombinant 
lentivirus was generated by co-transfecting 293FT cells 
with shSox9 from Sigma-Aldrich Mission® shRNA bacterial 
glycerol stock, Clone IDs: TRCN0000020386 (shSox9#386) 
and TRCN0000020388 (shSox9#388) or non-target control 
(NTC) plasmids and packaging plasmid mix (System 
Biosciences, Mountain View, CA). Viral supernatant was 
collected and used to infect Huh7 and Hep3B. The infected 
cells were selected with puromycin (Sigma-Aldrich). For 
overexpression study, either Sox9 expression construct 
(SC321884: NM_000346, human cDNA clone) or empty 
vector (Origene Technologies, Rockville, MD) were 
transfected into SMMC-7721 using Lipofectamine® 2000. 
Antibodies
Anti-Sox9 antibody was purchased from Millipore 
(AB5535, Billerica, MA). Anti-β-catenin and glycogen 
synthase kinase 3β (GSK3β) antibodies were obtained 
from BD Transduction Laboratories (#610153 & #610201, 
San Jose, CA). Anti-Oct4, Sox2 and FZD7 antibodies were 
purchased from Abcam (ab19857, ab97959 & ab51049, 
Cambridge, UK). Anti-E-cadherin, vimentin and phospho-
GSK3β (Ser9) antibodies were obtained from Cell Signaling 
Technology (#3195, #5741 & #9336, Beverly, MA, USA). 
Anti-β-actin antibody was purchased from Sigma-Aldrich 
(A5316, St. Louis, MO, USA). Anti-CD24 (ab30350, Abcam), 
E-cadherin (#610181, BD Transduction Laboratories) and 
vimentin antibodies (M0725, Dako, Glostrup, Denmark) were 
used for immunofluorescent staining. Anti-CK19 (ab52625, 
Abcam), anti-AFP (A0008, Dako) and anti-EpCAM (M0804, 
Dako) were used for immunohistochemistry.
Immunohistochemistry (IHC)
Immunohistochemical staining for Sox9, CK19, AFP 
and EpCAM were performed on formalin-fixed, paraffin-
embedded sections using labeled horseradish peroxidase 
(HRP) method. After heat antigen retrieval with Tris-
EDTA buffer (Sox9, CK19 & AFP) or Protease K enzyme 
antigen retrieval (EpCAM), endogenous peroxidase 
activities were quenched by 3% H2O2. The sections were 
immersed in serum free-protein block solution (Dako) and 
incubated with anti-Sox9 (dilution 1:1000), anti-CK19 
(dilution 1:1000), anti-AFP (dilution 1:6000) and anti-
EpCAM (dilution 1:100) at 4oC overnight. The sections 
were thoroughly washed and incubated with EnvisionTM 
HRP-conjugated secondary antibody (Dako). Positive 
signals were visualized using 3,3′-diaminobenzidine 
(Dako). Nuclei were counterstained with hematoxylin.
Western blotting
Whole cell lysates from cell lines were extracted 
using RIPA with protease and phosphatase inhibitors 
(Roche, Mannheim, Germany). The concentration 
of protein lysates was determined by Bradford assay 
(BioRad, Hercules, CA). Protein were separated by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 
transferred to polyvinylidene difluoride membrane 
(Millipore), blocked and incubated with primary 
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antibodies. HRP-conjugated anti-rabbit or anti-mouse 
IgG were used where appropriate (GE Healthcare Life 
Sciences, Piscataway, NJ). The signals were visualized 
using enhanced chemiluminescence method. 
RNA extraction and quantitative reverse-
transcription polymerase chain reaction (qPCR)
Total RNA was extracted using Trizol reagent (Life 
Technologies) according to manufacturer’s protocol. One 
microgram of RNA was used for cDNA synthesis using 
GeneAmp RNA PCR Kit (Applied Biosystems, Life 
Technologies). Expression of Sox9 of clinical samples 
was examined using TaqMan® Assay target probes (Assay 
ID: Hs01001343_g1), normalized using 18s rRNA 
(#4319413E, Applied Biosystems, Life Technologies). 
Expression of chemoresistance-related genes, stemness-
associated genes, c-myc and axin2 was examined by 
Power SYBR® Green PCR Master Mix (#4367659, 
Applied Biosystems, Life Technologies) using the 
primers indicated in Supplementary Table S3 with Applied 
Biosystems 7900HT Fast Real-Time PCR System.
Immunofluorescent (IF) staining
Cells of interest grown on chamber slides were fixed 
and permeabilized. Following blocking with 10% goat 
and donkey serum (G9023 and D9663, Sigma-Aldrich), 
they were incubated with primary antibodies overnight at 
4oC. The slides were washed and incubated with Alexa-
Fluor®-488 donkey anti-mouse IgG and Alexa-Fluor®-568 
goat anti-rabbit IgG (A21202 and A11011, Molecular 
Probes®, Invitrogen) together with 4’,6-Diamidino-2-
Phenylindole (DAPI) (D-1306, Molecular Probes®) for 
nucleus staining. All images were captured using Zeiss 
LSM700 inverted confocal microscope (Gottingen, 
Germany) at Faculty Core Facility, Li Ka Shing Faculty 
of Medicine, the University of Hong Kong.
Cell proliferation assay
Proliferation assay was performed using cell 
counting method. HCC cells were seeded at 5 × 103 per 
well into 24-well plate and counted in triplicates each day 
for seven days.
Cell invasion and migration transwell assays
Migration assays were performed using polycarbonate 
membrane transwell inserts with pore size of 8.0 μm. Invasion 
assays were performed using Matrigel (BD Biosciences) 
coated transwell inserts. Cells in serum free medium 
were seeded in upper chamber while the lower chamber 
was filled with medium supplemented with 10% FBS as 
chemoattractant. The transwell membranes were harvested 
after 24 hours, fixed and stained with 1% crystal violet. The 
membranes were cleaned, air-dried and mounted. The number 
of cells migrated or invaded was counted in 5 random fields.
Tumorsphere formation assay
Five hundreds HCC cells were seeded to 24-
well plates coated with polyHEMA (Sigma Aldrich). 
Cells were grown in DMEM/F12 medium (Invitrogen, 
Life Technologies) supplemented with 4 μg/mL insulin 
(Sigma-Aldrich), 20 ng/mL EGF (Sigma-Aldrich), B27 
(Invitrogen, Life Technologies) and 20 ng/mL basic FGF 
(Invitrogen, Life Technologies) for either 10 days (Huh7) 
or 15 days (Hep3B). For the secondary propagation 
of primary tumorspheres, primary tumorspheres were 
collected by centrifugation. The tumorspheres collected 
were washed with PBS, subsequently subjected to 
centrifugation and dissociated to single cell suspension 
using trypsin. After inactivating the trypsin, the cells were 
resuspended with DMEM/F12 medium with the above 
supplements and cultured in polyHEMA-coated plates.
Side population analysis
HCC cells were detached and suspended at 1 × 106 
cells/mL in DMEM medium supplemented with 2% FBS 
and 10 mM HEPES (pH 7.4). These cells were incubated at 
37oC for 90 minutes with 5 μg/mL Hoechst 33342 (Sigma-
Aldrich), either alone or in the presence of 5 μM of ABC-
transporter inhibitor Reserpine (Sigma-Aldrich). After 
incubation, the cells were co-stained with 5 μg/mL propidium 
iodide for dead cell exclusion (BD PharmingenTM). The cells 
were rinsed with ice-cold PBS supplemented with 2% FBS 
and 10 mM HEPES (pH 7.4) buffer. Cell analysis and data 
acquisition was performed with FACS Aria SORP cytometer 
(BD Biosciences) using DIVA software. 
Annexin V-apoptosis assay
HCC cells were treated with either doxorubicin or 
cisplatin in serum free condition for 24 hours. Apoptosis 
assays were performed using Annexin V-FITC Apoptosis 
Detection Kit I (556547, BD Pharmingen™) according to 
manufacturer’s protocol. The stained cells were subjected to 
analyses using either FACSCantoII Analyzer or FACSCalibur 
flow cytometer and CellQuest software (BD BioSciences).
β-catenin TCF binding assay 
The effect of Sox9 towards β-catenin activity was 
examined using luciferase reporter assay of TCF/LEF-
dependent transcription. Either 1.0 μg Firefly luciferase 
pSuper8XTOPflash or pSuper8XFOPflash constructs 
(gifts from Dr. Moon R, University of Washington, 
USA) together with 0.2 μg Renilla luciferase pRL-
CMV construct (Promega, Madison, WI, USA) were 
transfected into HCC cells using Lipofectamine® 2000. 
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Luciferase activities were assayed using Dual-Luciferase® 
Reporter Assay System (E1910, Promega) according to 
manufacturer’s protocol. 
In vivo subcutaneous xenograft inoculation 
The study protocol was approved by the Committee 
of the Use of Live Animals in Teaching and Research at 
the University of Hong Kong. One million of either NTC 
or shSox9#386 Huh7 cells were injected subcutaneously 
at both sides of posterior flanks of 4- to 6-week old male 
non-obese diabetic (NOD)/SCID mice (NOD.CB17-
Prkdcscid/J). For limited dilution assay and β-catenin 
overexpression rescue-experiment, 5 × 103, 1 × 104 or 
5 × 104 cells were injected subcutaneously into the mice. 
Tumor volume was calculated by the formula length × 
width2 × 0.5. Mice were sacrificed at 4 weeks (1 × 106 
cells), 70 days (5 × 103 cells), 75 or 60 days (1 × 104 cells) 
or 57 days (5 × 104 cells) and tumor bulks were harvested. 
All experiments were performed according to the Animals 
(Control of experiments) Ordinance (Hong Kong).
In vivo tail vein injection 
One million of either NTC or shSox9#386 
luciferase-labeled BEL-7402 cells were injected into the 
tail vein of 6-week old NOD/SCID mice. Ex vivo lung 
metastases were recorded using IVIS 100 Imaging System 
(Xenogen, Hopkinton, MA) at week 12 after anesthetizing 
and injecting 100 mg/kg D-luciferin intraperitoneally into 
the mice. Lung tissues were harvested for histological 
analyses.
Chromatin immunoprecipitation (ChIP) assay 
ChIP assay was carried out according to the 
manufacturer’s protocol (ChIP assay Kit, Millipore). The 
precleared lysates were immunoprecipitated with Sox9 
antibody and normal rabbit IgG (sc-2027, Santa Cruz). 
The pull-down purified DNA was quantified using qPCR, 
with the primers indicated in Supplementary Table S4.
Luciferase reporter assay 
The regions of interest of Frizzled-7 were amplified 
using the primers indicated in Supplementary Table S5 
and cloned into pGL3-Basic construct (Promega). Cloned 
construct together with pRL-CMV were transfected 
into the cells of interest. The cells were harvested after 
24 hours and luciferase activities were measured using 
Dual-Luciferase® Reporter Assay System. 
Statistical analysis 
Statistical analysis for clinicopathological corre-
lation was performed using SPSS 19 for Windows (SPSS, 
Inc., Chicago, IL). Fisher’s exact test was used for 
categorical data. Survival curves of Sox9 overexpression 
(T/NT at 4-fold cutoff) were determined by the Kaplan-
Meier method, and the statistical difference between 
two groups was evaluated by the Log-rank test. All 
experimental data were analyzed using t test or Mann-
Whitney’s U test wherever appropriate (SigmaPlot 10.0 
and SigmaStat 3.1, Jandel Scientific, San Rafael, CA; 
or GraphPad Prism 5.0, La Jolla, CA, USA). Statistical 
significance was defined by p < 0.05. 
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